These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 23763830)

  • 1. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer.
    Lavoué V; Thédrez A; Levêque J; Foucher F; Henno S; Jauffret V; Belaud-Rotureau MA; Catros V; Cabillic F
    J Transl Med; 2013 Jun; 11():147. PubMed ID: 23763830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunotherapy in epithelial ovarian carcinoma: hope and reality].
    Lavoué V; Foucher F; Henno S; Bauville E; Catros V; Cabillic F; Levêque J
    J Gynecol Obstet Biol Reprod (Paris); 2014 Mar; 43(3):198-210. PubMed ID: 24230482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer.
    Cândido EB; Silva LM; Carvalho AT; Lamaita RM; Filho RM; Cota BD; da Silva-Filho AL
    Reprod Sci; 2013 Jul; 20(7):828-37. PubMed ID: 23239818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II.
    Mazumder S; Johnson JM; Swank V; Dvorina N; Martelli E; Ko J; Tuohy VK
    Cancer Prev Res (Phila); 2017 Nov; 10(11):612-624. PubMed ID: 29093011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sub-optimal primary surgery leads to unfavorable immunological changes in ovarian cancer patients.
    Nowak M; Głowacka E; Lewkowicz P; Banasik M; Szyłło K; Zimna K; Bednarska K; Klink M
    Immunobiology; 2018 Jan; 223(1):1-7. PubMed ID: 29017822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific immunotherapy in ovarian cancer: a systematic review.
    Aalipour S; Zoghi S; Khalili N; Hirbod-Mobarakeh A; Emens LA; Rezaei N
    Immunotherapy; 2016 Oct; 8(10):1193-204. PubMed ID: 27605068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.
    Vermeij R; de Bock GH; Leffers N; Ten Hoor KA; Schulze U; Hollema H; van der Burg SH; van der Zee AG; Daemen T; Nijman HW
    J Immunother; 2011; 34(6):516-23. PubMed ID: 21654520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor.
    Nishio H; Yaguchi T; Sugiyama J; Sumimoto H; Umezawa K; Iwata T; Susumu N; Fujii T; Kawamura N; Kobayashi A; Park J; Aoki D; Kawakami Y
    Br J Cancer; 2014 Jun; 110(12):2965-74. PubMed ID: 24867687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
    Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
    Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
    Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.
    Sucheston-Campbell LE; Cannioto R; Clay AI; Etter JL; Eng KH; Liu S; Battaglia S; Hu Q; Szender JB; Minlikeeva A; Joseph JM; Mayor P; Abrams SI; Segal BH; Wallace PK; Soh KT; Zsiros E; Anton-Culver H; Bandera EV; Beckmann MW; Berchuck A; Bjorge L; Bruegl A; Campbell IG; Campbell SP; Chenevix-Trench G; Cramer DW; Dansonka-Mieszkowska A; Dao F; Diergaarde B; Doerk T; Doherty JA; du Bois A; Eccles D; Engelholm SA; Fasching PA; Gayther SA; Gentry-Maharaj A; Glasspool RM; Goodman MT; Gronwald J; Harter P; Hein A; Heitz F; Hillemmanns P; Høgdall C; Høgdall EV; Huzarski T; Jensen A; Johnatty SE; Jung A; Karlan BY; Klapdor R; Kluz T; Konopka B; Kjær SK; Kupryjanczyk J; Lambrechts D; Lester J; Lubiński J; Levine DA; Lundvall L; McGuire V; McNeish IA; Menon U; Modugno F; Ness RB; Orsulic S; Paul J; Pearce CL; Pejovic T; Pharoah P; Ramus SJ; Rothstein J; Rossing MA; Rübner M; Schildkraut JM; Schmalfeldt B; Schwaab I; Siddiqui N; Sieh W; Sobiczewski P; Song H; Terry KL; Van Nieuwenhuysen E; Vanderstichele A; Vergote I; Walsh CS; Webb PM; Wentzensen N; Whittemore AS; Wu AH; Ziogas A; Odunsi K; Chang-Claude J; Goode EL; Moysich KB;
    Cancer Epidemiol Biomarkers Prev; 2017 Mar; 26(3):420-424. PubMed ID: 27677730
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunotherapy opportunities in ovarian cancer.
    Chu CS; Kim SH; June CH; Coukos G
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):243-57. PubMed ID: 18279065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of the Mac-1 expression on peripheral blood neutrophils in patients with different types of epithelial ovarian cancer.
    Bednarska K; Klink M; Wilczyński JR; Szyłło K; Malinowski A; Sułowska Z; Nowak M
    Immunobiology; 2016 Feb; 221(2):323-32. PubMed ID: 26563750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer.
    Lundgren S; Berntsson J; Nodin B; Micke P; Jirström K
    J Ovarian Res; 2016 Apr; 9():21. PubMed ID: 27048364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
    Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
    Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.
    Peng DX; Luo M; Qiu LW; He YL; Wang XF
    Oncol Rep; 2012 Apr; 27(4):1238-44. PubMed ID: 22246341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.
    Thedrez A; Lavoué V; Dessarthe B; Daniel P; Henno S; Jaffre I; Levêque J; Catros V; Cabillic F
    PLoS One; 2013; 8(5):e63322. PubMed ID: 23717410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
    Ma Z; Wang X; He J; Xia J; Li Y
    PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells.
    Valmori D; Qian F; Ayyoub M; Renner C; Merlo A; Gnjatic S; Stockert E; Driscoll D; Lele S; Old LJ; Odunsi K
    Clin Cancer Res; 2006 Jan; 12(2):398-404. PubMed ID: 16428478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.